A sharp decline in revenues from rapid COVID-19 antigen tests contributed to a decline of almost 6% in revenues for the third fiscal quarter at Siemens Healthineers. The company reported "solid" growth from its imaging and radiation oncology businesses.
For the quarter (end-30 June), Siemens Healthineers posted third-quarter revenues of 5.186 billion euros, down 5.7% after currency adjustment compared with revenues of 5 billion euros the year before. The company's net income for the quarter was 364 million euros, down 8% compared with net income of 395 million euros in the same quarter the year before.
The company said that revenues fell due to "markedly lower" revenue from rapid COVID-19 antigen tests, and what the company called a "challenging environment" due mostly to pandemic lockdowns in China. Excluding COVID tests, the company's revenue would have grown 0.9% after currency adjustment.
The Diagnostics business reported sales of 1.409 billion euros, down 23.9% after currency adjustment compared with 1.72 billion euros in the third quarter of fiscal 2021. The division's adjusted earnings before interest and taxes (EBIT) were 178 million euros, compared with 360 million euros the previous year.
The company said the most recent quarter suffered from comparison to the third quarter of 2021, which Siemens called an "outstanding prior-year period." Sales of COVID-19 rapid antigen tests contributed revenues of 300 million euros most recently, compared with 600 million euros in the second quarter of 2021.
In its Imaging business, Siemens saw revenue grow 2.5% after currency adjustment, to 2.602 billion euros in the most recent quarter compared with 2.376 billion euros the corresponding quarter of 2021. The division's adjusted EBIT for the quarter was 478 million euros, compared with 430 million euros in the same period of 2021.
On a modality basis, Siemens said that its MRI segment posted "very strong" growth, while revenues in molecular imaging and ultrasound fell due to disruptions in the supply chain related to pandemic lockdowns. Geographically, the Imaging business saw strong growth in the Americas region while the Europe, Middle East, and Africa (EMEA) region recorded slight growth and revenue fell slightly in the Asia/Australia region due to lockdowns in China.
The company's Varian radiation oncology segment saw revenues of 800 million euros, up 8.2% after currency adjustment compared with sales of 591 million euros in the second quarter of 2021. The division's adjusted EBIT was 107 million euros, compared with 98 million euros the corresponding quarter the year before.
